ASH 2023 – the search for a better Ayvakit
Blueprint looks to a next-gen Ayvakit, while Cogent challenges with a molecule acquired from Daiichi Sankyo.
Blueprint looks to a next-gen Ayvakit, while Cogent challenges with a molecule acquired from Daiichi Sankyo.
But JNJ-75276617 still has much to prove.
Merck sees clinical setbacks in Keylynk-008, Leap-001 and Keyvibe-002.
Arvinas’s SERD appears to edge out Olema’s, but what’s the best CDK4/6 inhibitor for a phase 3 combination?
The company hopes that new edits could solve the relapse problem with allogeneic Car-Ts.
With inavolisib’s pivotal front-line win Roche reckons it can knock out Novartis’s Piqray.
Merus still hopes for a future for MCLA-129, but the doors are closing.
Jaypirca secures a CLL label, though plans to dominate will be tempered by this market’s fast-changing nature.
Yet another ADC deal sees AbbVie buy ImmunoGen, ending a 40-year rollercoaster ride with a 100% overnight premium.
But the FDA’s investigation looks like worse news for autoimmune disease than oncology.